Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 345

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 345
---
 at the Diagnostics Solutions division of Hologic, a medical technology
company primarily focused on improving women’s health through early detection and treatment. At Hologic, Dr. Denisenko oversaw a
portfolio of new product development projects encompassing molecular diagnostics of infectious diseases and cancer, including instrumentation.
Previously, Dr. Denissenko led New Product Portfolio Management at Prometheus Labs, a Nestlé Health Science Company that employed
both Dx and Rx approaches to improve human condition in gastrointestinal and liver diseases. Prior to Prometheus, Dr. Denissenko was a
head of strategic innovation, technology assessment, and product development for Molecular and Cellular Essentials business platform at
Thermo Fisher Scientific; was on Drug Discovery management team in the Pharmaceuticals division at Sequenom; and led an R&D group
involved in the development and production of commercial bioreagents at BD Biosciences. During his career in the life sciences industry,
Dr. Denissenko had advanced Product Lifecycle Management beyond being a mere toolset and established it as a key business approach, thus
facilitating innovation and driving product development. Dr. Denissenko is also a founder of two biotech startup companies and an author
of over 40 peer-reviewed publications, including a seminal Science paper (>1,960 citations), and several book chapters.

Kevin Krenitsky, MD.From
2015-2016, Kevin Krenitsky served as President of OpGen (NASDAQ:OPGN) and oversaw the rollout of the company’s Acuitas
MDRO family of Gene Tests and the development of Acuitas Lighthouse™ MDRO Management System. Dr. Krenitsky has more than 15 years
of experience leading and managing global diagnostic and biotechnology operations, including as Chief Commercial Officer & SVP of
International Strategy and previously Chief Operating Officer of Foundation Medicine (NASDAQ: FMI). Prior to Foundation Medicine, he served
as President of Enzo Clinical Labs, a wholly owned subsidiary of Enzo Biochem (NYSE:ENZ), where he instituted a comprehensive strategic
and operational plan that led to the launch of numerous FDA-approved esoteric tests, as well as several new laboratory developed tests.
Dr. Krenitsky served as Chief Executive Officer at both BioServe Biotechnologies, a global biotechnology company specializing in processing
genetic diagnostic tests, and Parkway Clinical Laboratories, a clinical diagnostic lab providing comprehensive routine and esoteric testing.
He also held various senior-level positions within Genomics Collaborative, Inc. (a S